JP6059014B2 - 試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ - Google Patents
試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ Download PDFInfo
- Publication number
- JP6059014B2 JP6059014B2 JP2012516358A JP2012516358A JP6059014B2 JP 6059014 B2 JP6059014 B2 JP 6059014B2 JP 2012516358 A JP2012516358 A JP 2012516358A JP 2012516358 A JP2012516358 A JP 2012516358A JP 6059014 B2 JP6059014 B2 JP 6059014B2
- Authority
- JP
- Japan
- Prior art keywords
- array
- binding
- sample
- peptides
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 252
- 238000001514 detection method Methods 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000003491 array Methods 0.000 title description 41
- 239000000470 constituent Substances 0.000 title description 6
- 230000027455 binding Effects 0.000 claims description 262
- 238000009739 binding Methods 0.000 claims description 262
- 239000000523 sample Substances 0.000 claims description 184
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 118
- 208000015181 infectious disease Diseases 0.000 claims description 39
- 229960005486 vaccine Drugs 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 23
- 238000010494 dissociation reaction Methods 0.000 claims description 10
- 230000005593 dissociations Effects 0.000 claims description 10
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 108090000144 Human Proteins Proteins 0.000 claims description 4
- 102000003839 Human Proteins Human genes 0.000 claims description 4
- 244000000010 microbial pathogen Species 0.000 claims description 4
- 239000013074 reference sample Substances 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 231
- 201000010099 disease Diseases 0.000 description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 89
- 238000012360 testing method Methods 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- 230000003053 immunization Effects 0.000 description 24
- 238000002649 immunization Methods 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 21
- 230000003993 interaction Effects 0.000 description 20
- 206010022000 influenza Diseases 0.000 description 17
- 230000009870 specific binding Effects 0.000 description 17
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000004422 calculation algorithm Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 238000002493 microarray Methods 0.000 description 12
- 230000001932 seasonal effect Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000000513 principal component analysis Methods 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 230000009871 nonspecific binding Effects 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 231100000636 lethal dose Toxicity 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 208000037797 influenza A Diseases 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012706 support-vector machine Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000003486 coccidioidomycosis Diseases 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- -1 at least 1% Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- AKIZPWSPNKVOMT-UHFFFAOYSA-N 1-sulfanylhexan-1-ol Chemical compound CCCCCC(O)S AKIZPWSPNKVOMT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000223203 Coccidioides Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010049175 N-substituted Glycines Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- CJEILOKBNGURRL-CEOVSRFSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid;(2r)-2-amino-3-sulfanylpropanoic acid Chemical group NCC(O)=O.OC[C@H](N)C(O)=O.SC[C@H](N)C(O)=O CJEILOKBNGURRL-CEOVSRFSSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000983850 Homo sapiens Phosphatidate phosphatase LPIN3 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 102100025728 Phosphatidate phosphatase LPIN3 Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 108010073131 cystic fibrosis serum factor Proteins 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229940031689 heterologous vaccine Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000003368 label free method Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002110 nanocone Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000004284 spotted fever Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21889009P | 2009-06-19 | 2009-06-19 | |
| US61/218,890 | 2009-06-19 | ||
| US24914709P | 2009-10-06 | 2009-10-06 | |
| US61/249,147 | 2009-10-06 | ||
| PCT/US2010/039269 WO2010148365A2 (en) | 2009-06-19 | 2010-06-18 | Compound arrays for sample profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238364A Division JP2017067789A (ja) | 2009-06-19 | 2016-12-08 | 化合物のアレイ及びそれを用いて試料を分析する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530906A JP2012530906A (ja) | 2012-12-06 |
| JP2012530906A5 JP2012530906A5 (enExample) | 2013-08-01 |
| JP6059014B2 true JP6059014B2 (ja) | 2017-01-11 |
Family
ID=43357083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516358A Active JP6059014B2 (ja) | 2009-06-19 | 2010-06-18 | 試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ |
| JP2016238364A Pending JP2017067789A (ja) | 2009-06-19 | 2016-12-08 | 化合物のアレイ及びそれを用いて試料を分析する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238364A Pending JP2017067789A (ja) | 2009-06-19 | 2016-12-08 | 化合物のアレイ及びそれを用いて試料を分析する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (6) | US20120190574A1 (enExample) |
| EP (1) | EP2443459B1 (enExample) |
| JP (2) | JP6059014B2 (enExample) |
| WO (1) | WO2010148365A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617611B2 (en) | 2011-03-28 | 2017-04-11 | Ipsen, Inc. | Quenching process and apparatus for practicing said process |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5501445B2 (ja) | 2009-04-30 | 2014-05-21 | ペイシェンツライクミー， インコーポレイテッド | オンラインコミュニティ内のデータ提出を促進するシステムおよび方法 |
| US20120190574A1 (en) | 2009-06-19 | 2012-07-26 | The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona | Compound Arrays for Sample Profiling |
| AU2013308682A1 (en) * | 2012-08-29 | 2015-03-12 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Immunosignaturing: a path to early diagnosis and health monitoring |
| US20150241420A1 (en) * | 2012-09-05 | 2015-08-27 | Arizona Board of Regents, Body Corp. of the State of Arizona, acting for and on behalf of Arizona S | Methods for discovering therapeutic targets |
| AU2016251501A1 (en) | 2015-04-20 | 2017-10-19 | F. Hoffmann-La Roche Ag | Specific peptide binders to proteins identified via systemic discovery, maturation and extension process |
| US10176426B2 (en) | 2015-07-07 | 2019-01-08 | International Business Machines Corporation | Predictive model scoring to optimize test case order in real time |
| US10758886B2 (en) | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
| AU2017281039A1 (en) * | 2016-06-20 | 2019-01-24 | Healthtell Inc. | Methods for differential diagnosis of autoimmune diseases |
| JP2019526786A (ja) * | 2016-06-20 | 2019-09-19 | ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． | 自己免疫疾患の診断および処置のための方法 |
| EP3523657B1 (en) | 2016-10-04 | 2023-06-21 | F. Hoffmann-La Roche AG | System and method for identification of a synthetic classifier |
| US11359112B2 (en) | 2016-11-09 | 2022-06-14 | Cowper Sciences Inc. | Coatings with tunable amine density |
| US12037311B2 (en) | 2016-11-09 | 2024-07-16 | Cowper Sciences Inc. | Pre-assembled, protected, chemically stable, chemoselective linkers |
| US11371990B2 (en) | 2016-11-11 | 2022-06-28 | Cowper Sciences Inc. | Methods for identifying candidate biomarkers |
| JP2020500517A (ja) | 2016-11-28 | 2020-01-16 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 連続流小滴反応に関連するシステムおよび方法 |
| US20210072255A1 (en) | 2016-12-16 | 2021-03-11 | The Brigham And Women's Hospital, Inc. | System and method for protein corona sensor array for early detection of diseases |
| PT3554681T (pt) | 2016-12-16 | 2022-03-21 | Brigham & Womens Hospital Inc | Método para matriz de sensores de coroa de proteínas para a deteção precoce de doenças |
| US10712342B2 (en) | 2017-01-31 | 2020-07-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic to distinguish bacterial infections |
| US12417825B2 (en) | 2017-09-15 | 2025-09-16 | Alden Scientific, Inc. | Systems and methods for collecting and analyzing comprehensive medical information |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| WO2019190954A1 (en) | 2018-03-26 | 2019-10-03 | Rootpath Genomics, Inc. | Target binding moiety compositions and methods of use |
| US11592440B2 (en) | 2018-07-27 | 2023-02-28 | Sysmex Corporation | Bioparticle measuring method |
| JP7153493B2 (ja) * | 2018-07-27 | 2022-10-14 | シスメックス株式会社 | 生体粒子の測定方法、非特異シグナルの検出方法、生体粒子測定方法及び生体粒子を検出するための試薬キット |
| US11205139B2 (en) | 2018-08-06 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Computational analysis to predict molecular recognition space of monoclonal antibodies through random-sequence peptide arrays |
| EP3861344A4 (en) * | 2018-10-01 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | HIGHLY SPECIFIC AND HIGHLY SENSITIVE DIAGNOSTIC IMMUNODORPTION TESTS WITH SIMULTANEOUS RESOLUTION OF MULTIPLE ANTIBODIES ISOTYPES |
| GB2595583A (en) | 2018-11-07 | 2021-12-01 | Seer Inc | Compositions, methods and systems for protein corona analysis and uses thereof |
| US11894139B1 (en) | 2018-12-03 | 2024-02-06 | Patientslikeme Llc | Disease spectrum classification |
| CA3131402A1 (en) | 2019-03-26 | 2020-10-01 | Xiaoyan Zhao | Compositions, methods and systems for protein corona analysis from biofluids and uses thereof |
| KR20240137114A (ko) | 2019-08-05 | 2024-09-19 | 시어 인코퍼레이티드 | 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법 |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| US20210333275A1 (en) * | 2020-03-23 | 2021-10-28 | Cdi Laboratories, Inc. | Pan-isotype immunoglobulin fingerprinting |
| JP7601324B2 (ja) * | 2020-06-02 | 2024-12-17 | 公立大学法人福島県立医科大学 | 化合物を基板上に固定する方法および固定化した化合物の検出方法 |
| JP2023540904A (ja) | 2020-08-25 | 2023-09-27 | シアー， インコーポレイテッド | タンパク質および核酸をアッセイするための組成物および方法 |
| EP4057006A1 (en) * | 2021-03-08 | 2022-09-14 | Universite De Bordeaux | Ex vivo method for analysing a tissue sample using proteomic profile matching, and its use for the diagnosis, prognosis of pathologies and for predicting response to treatments |
| US11752195B2 (en) * | 2021-04-15 | 2023-09-12 | Arizona Board Of Regents On Behalf Of Arizona State Univeristy | Compositions and methods of use of synthetic peptides with Mycobacterium abscessus inhibitory activity |
| US20250354988A1 (en) * | 2024-05-14 | 2025-11-20 | Nautilus Subsidiary, Inc. | Time-dependent profiling of binding interactions |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DK0600866T3 (da) | 1990-06-01 | 1998-03-09 | Chiron Corp | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler |
| DK0604552T3 (da) | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Fremgangsmåde til syntese af forskellige samlinger af oligomerer |
| US5677195A (en) | 1991-11-22 | 1997-10-14 | Affymax Technologies N.V. | Combinatorial strategies for polymer synthesis |
| EP0665897B1 (en) | 1992-10-01 | 2003-07-09 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| BR9407947A (pt) | 1993-11-02 | 1996-11-26 | Affymax Tech Nv | Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| PL185040B1 (pl) * | 1995-06-07 | 2003-02-28 | Affymax Tech Nv | Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego |
| US6706875B1 (en) | 1996-04-17 | 2004-03-16 | Affyemtrix, Inc. | Substrate preparation process |
| JP4663824B2 (ja) | 1996-12-31 | 2011-04-06 | ハイ スループット ジェノミクス インコーポレイテッド | 多重化分子分析装置および方法 |
| US5902475A (en) | 1997-04-08 | 1999-05-11 | Interventional Technologies, Inc. | Method for manufacturing a stent |
| US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| US6309831B1 (en) | 1998-02-06 | 2001-10-30 | Affymetrix, Inc. | Method of manufacturing biological chips |
| US6723517B1 (en) * | 1998-06-02 | 2004-04-20 | Minerva Biotechnologies Corporation | Use of self-assembled monolayers to probe the structure of a target molecule |
| US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
| US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| JP4355384B2 (ja) | 1999-01-14 | 2009-10-28 | キヤノン株式会社 | パターン露光方法、露光装置、核酸アレイの形成方法及びペプチドアレイの形成方法 |
| EA200100896A1 (ru) * | 1999-02-17 | 2002-04-25 | Гликоминдс Лтд. | Комбинаторные библиотеки сложных углеводов и способы их получения и использования |
| EP2360270B1 (en) | 1999-05-20 | 2016-11-09 | Illumina, Inc. | Combinatorial decoding of random nucleic acid arrays |
| US6573369B2 (en) | 1999-05-21 | 2003-06-03 | Bioforce Nanosciences, Inc. | Method and apparatus for solid state molecular analysis |
| KR20010001577A (ko) | 1999-06-07 | 2001-01-05 | 윤종용 | 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법 |
| US6660479B2 (en) | 1999-06-07 | 2003-12-09 | Samsung Electronics Co., Ltd. | Process for preparing peptide nucleic acid probe using polymeric photoacid generator |
| WO2000079326A1 (en) | 1999-06-18 | 2000-12-28 | Genomic Solutions Inc. | An automated, ccd-based microarray imaging system |
| AU5799500A (en) * | 1999-06-29 | 2001-01-22 | Mcgill University | Human alpha 1,2-mannosidase |
| US6465183B2 (en) * | 1999-07-01 | 2002-10-15 | Agilent Technologies, Inc. | Multidentate arrays |
| AU5912100A (en) * | 1999-07-02 | 2001-01-22 | Scripps Research Institute, The | Method for determination of peptide-binding agent interaction |
| US6824669B1 (en) | 2000-02-17 | 2004-11-30 | Motorola, Inc. | Protein and peptide sensors using electrical detection methods |
| US20020098513A1 (en) * | 2000-02-17 | 2002-07-25 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
| US20100184620A1 (en) * | 2000-02-24 | 2010-07-22 | Leszek Rychlewski | Method of biological and medical diagnostics using immune patterns obtained with arrays of peptide probes |
| US6413722B1 (en) | 2000-03-22 | 2002-07-02 | Incyte Genomics, Inc. | Polymer coated surfaces for microarray applications |
| US8399383B2 (en) | 2000-05-04 | 2013-03-19 | Yale University | Protein chips for high throughput screening of protein activity |
| US7148058B2 (en) | 2000-06-05 | 2006-12-12 | Chiron Corporation | Protein microarrays on mirrored surfaces for performing proteomic analyses |
| US6511277B1 (en) | 2000-07-10 | 2003-01-28 | Affymetrix, Inc. | Cartridge loader and methods |
| US6890760B1 (en) | 2000-07-31 | 2005-05-10 | Agilent Technologies, Inc. | Array fabrication |
| US6545758B1 (en) | 2000-08-17 | 2003-04-08 | Perry Sandstrom | Microarray detector and synthesizer |
| US6567163B1 (en) | 2000-08-17 | 2003-05-20 | Able Signal Company Llc | Microarray detector and synthesizer |
| US7354721B2 (en) | 2000-09-22 | 2008-04-08 | Clontech Laboratories, Inc. | Highly sensitive proteomic analysis methods, and kits and systems for practicing the same |
| US7130458B2 (en) | 2000-10-24 | 2006-10-31 | Affymetrix, Inc. | Computer software system, method, and product for scanned image alignment |
| US6877665B2 (en) | 2000-11-20 | 2005-04-12 | Ecrio, Inc. | System, method, and apparatus for communicating information encoded in a light-based signal using a fob device |
| WO2002090985A1 (en) | 2001-05-07 | 2002-11-14 | Kiyoshi Nokihara | Peptide-immobilized baseboard and method of assaying target protein using the same |
| US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
| US7695919B2 (en) | 2001-05-10 | 2010-04-13 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| USRE44031E1 (en) | 2001-05-10 | 2013-02-26 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| US20050009204A1 (en) * | 2003-07-11 | 2005-01-13 | Ye Fang | Multiplexed binding assays for receptor arrays |
| EP1402064A4 (en) * | 2001-05-30 | 2005-08-24 | Gene Therapy Systems Inc | PROTEIN ARRAYS AND METHOD AND SYSTEMS FOR THEIR PRODUCTION |
| US6989267B2 (en) | 2001-07-02 | 2006-01-24 | Agilent Technologies, Inc. | Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films |
| US20050048566A1 (en) | 2001-08-27 | 2005-03-03 | Delisi Charles | Apparatus, composition and method for proteome profiling |
| US9222938B2 (en) | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| WO2003062402A2 (en) * | 2002-01-24 | 2003-07-31 | Pointilliste, Inc. | Use of collections of binding sites for sample profiling and other applications |
| US6919181B2 (en) | 2002-03-25 | 2005-07-19 | Agilent Technologies, Inc. | Methods for generating ligand arrays |
| US7006680B2 (en) | 2002-05-03 | 2006-02-28 | Vialogy Corp. | System and method for characterizing microarray output data |
| AU2003302118A1 (en) * | 2002-05-10 | 2004-06-15 | Epitome Biosystems, Inc. | Unique recognition sequences and methods of use thereof in protein analysis |
| US20040071705A1 (en) * | 2002-06-21 | 2004-04-15 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| EP1552003A4 (en) | 2002-06-28 | 2007-06-13 | Rosetta Inpharmatics Llc | METHOD FOR ASSESSING THE QUALITY OF MICROARRAYS |
| US8073626B2 (en) | 2003-01-31 | 2011-12-06 | Agilent Technologies, Inc. | Biopolymer array reading |
| US7534563B2 (en) | 2003-06-30 | 2009-05-19 | Agilent Technologies, Inc. | Methods for producing ligand arrays |
| CA2533659A1 (en) * | 2003-07-25 | 2005-03-10 | Platypus Technologies, Llc | Liquid crystal based analyte detection |
| WO2005050224A2 (en) * | 2003-11-13 | 2005-06-02 | Epitome Biosystems Inc. | Small molecule and peptide arrays and uses thereof |
| EP1692506A4 (en) * | 2003-11-17 | 2008-01-09 | Janssen Pharmaceutica Nv | MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION |
| DE602005023710D1 (de) * | 2004-02-20 | 2010-11-04 | Japan Science & Tech Agency | Dna-array zur analyse der dna-methylierung, konstruktionsverfahren dafür sowie verfahren zur analyse der dna-methylierung |
| US7588906B2 (en) | 2004-02-24 | 2009-09-15 | Wisconsin Alumni Research Foundation | Hydrogels for biomolecule analysis and corresponding method to analyze biomolecules |
| US20070003954A1 (en) | 2005-05-12 | 2007-01-04 | The Board Of Regents Of The University Of Texas System | Protein and antibody profiling using small molecule microarrays |
| US20070015172A1 (en) | 2005-06-01 | 2007-01-18 | Z-Biomed, Inc. | Expression profiles for microbial infection |
| US20070099256A1 (en) | 2005-10-28 | 2007-05-03 | Narayan Sundararajan | Chemical derivatization, detection, and identification of peptide and protein modifications |
| US7923054B2 (en) * | 2006-04-19 | 2011-04-12 | Gore Enterprise Holdings, Inc. | Functional porous substrates for attaching biomolecules |
| CA2655563A1 (en) * | 2006-06-15 | 2007-12-21 | Van Andel Research Institute | Methods for detecting molecular complexes |
| US8242058B2 (en) | 2006-07-21 | 2012-08-14 | Wisconsin Alumni Research Foundation | Reagents and methods for appending functional groups to proteins |
| US8088596B2 (en) * | 2006-10-10 | 2012-01-03 | Oakland University | Method of microorganism detection using carbohydrate and lectin recognition |
| US20110143953A1 (en) * | 2006-10-16 | 2011-06-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Synthetic Antibodies |
| US7622295B2 (en) | 2006-12-19 | 2009-11-24 | Edelmira Cabezas | Molecular microarrays and helical peptides |
| WO2008151146A2 (en) * | 2007-06-01 | 2008-12-11 | Digitab, Inc. | Peptide arrays and methods of use |
| US20110046015A1 (en) | 2008-01-29 | 2011-02-24 | Hiroyuki Honda | Peptide immobilization solution and use thereof |
| WO2009140039A2 (en) | 2008-04-23 | 2009-11-19 | The Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Synthetic antibodies |
| US7993583B2 (en) | 2008-10-29 | 2011-08-09 | Lawrence Livermore National Security, Llc | Passive microfluidic array card and reader |
| US20120190574A1 (en) | 2009-06-19 | 2012-07-26 | The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona | Compound Arrays for Sample Profiling |
| WO2011016829A1 (en) * | 2009-08-06 | 2011-02-10 | Albert Einstein College Of Medicine Of Yeshiva University | Cell therapy for treatment of liver failure |
| US8969009B2 (en) | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| WO2011153464A2 (en) | 2010-06-03 | 2011-12-08 | New York University | In situ oriented immobilization of proteins on a support |
| TW201144805A (en) | 2010-06-08 | 2011-12-16 | Academia Sinica | Microfluidic device |
| US9346892B2 (en) | 2011-03-18 | 2016-05-24 | Roche Nimble Gen, Inc. | Methods for synthesis of an oligopeptide microarray |
| US10046293B2 (en) | 2012-10-17 | 2018-08-14 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | In situ chemical patterning |
-
2010
- 2010-06-18 US US13/379,080 patent/US20120190574A1/en not_active Abandoned
- 2010-06-18 JP JP2012516358A patent/JP6059014B2/ja active Active
- 2010-06-18 WO PCT/US2010/039269 patent/WO2010148365A2/en not_active Ceased
- 2010-06-18 EP EP10790305.6A patent/EP2443459B1/en not_active Not-in-force
-
2012
- 2012-09-21 US US13/624,332 patent/US10422793B2/en active Active
- 2012-09-21 US US13/624,386 patent/US9709558B2/en active Active
- 2012-11-21 US US13/683,778 patent/US8969255B2/en active Active
-
2016
- 2016-12-08 JP JP2016238364A patent/JP2017067789A/ja active Pending
-
2017
- 2017-06-13 US US15/621,877 patent/US20170343541A1/en not_active Abandoned
-
2019
- 2019-04-08 US US16/378,334 patent/US20190271692A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617611B2 (en) | 2011-03-28 | 2017-04-11 | Ipsen, Inc. | Quenching process and apparatus for practicing said process |
Also Published As
| Publication number | Publication date |
|---|---|
| US8969255B2 (en) | 2015-03-03 |
| JP2012530906A (ja) | 2012-12-06 |
| US20130143756A1 (en) | 2013-06-06 |
| US20130079250A1 (en) | 2013-03-28 |
| US20190271692A1 (en) | 2019-09-05 |
| US20170343541A1 (en) | 2017-11-30 |
| US20130079242A1 (en) | 2013-03-28 |
| US20120190574A1 (en) | 2012-07-26 |
| WO2010148365A2 (en) | 2010-12-23 |
| US9709558B2 (en) | 2017-07-18 |
| JP2017067789A (ja) | 2017-04-06 |
| EP2443459A2 (en) | 2012-04-25 |
| EP2443459B1 (en) | 2018-12-26 |
| EP2443459A4 (en) | 2013-09-18 |
| WO2010148365A3 (en) | 2011-05-19 |
| US10422793B2 (en) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017067789A (ja) | 化合物のアレイ及びそれを用いて試料を分析する方法 | |
| AU2019204047C1 (en) | Immunosignaturing: a path to early diagnosis and health monitoring | |
| US11067582B2 (en) | Peptide array quality control | |
| US9970932B2 (en) | Non-covalent patterned chemical features and use thereof in MALDI-based quality control | |
| Legutki et al. | A general method for characterization of humoral immunity induced by a vaccine or infection | |
| CN110187122A (zh) | 发现治疗靶标的方法 | |
| US20250130231A1 (en) | Compositions and methods for detection and treatment of coronavirus infection | |
| Jaago et al. | Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals | |
| US10416174B1 (en) | Diagnosis and prognosis for chronic fatigue syndrome | |
| Huang et al. | Initiator integrated poly (dimethysiloxane)-based microarray as a tool for revealing the relationship between nonspecific interactions and irreproducibility | |
| Hotop et al. | Serological analysis of herpes B virus at individual epitope resolution: from two-dimensional peptide arrays to multiplex bead flow assays | |
| Halperin | Characterization and analysis of a novel platform for profiling the antibody response | |
| CN103517714A (zh) | 用于刚地弓形虫感染和弓形体病的诊断和治疗的方法和蛋白抗原组合物 | |
| HK40006694A (en) | Methods for discovering therapeutic targets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130617 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140722 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141022 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160524 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161014 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6059014 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |